دورية أكاديمية
Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal cancer treatment (ICON8): overall survival results from an open-label, randomised, controlled, phase 3 trial.
| العنوان: | Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal cancer treatment (ICON8): overall survival results from an open-label, randomised, controlled, phase 3 trial. |
|---|---|
| المؤلفون: | Clamp, AR, James, EC, McNeish, IA, Dean, A, Kim, J-W, O'Donnell, DM, Gallardo-Rincon, D, Blagden, S, Brenton, J, Perren, TJ, Sundar, S, Lord, R, Dark, G, Hall, M, Banerjee, S, Glasspool, RM, Hanna, CL, Williams, S, Scatchard, KM, Nam, H, Essapen, S, Parkinson, C, McAvan, L, Swart, AM, Popoola, B, Schiavone, F, Badrock, J, Fananapazir, F, Cook, AD, Parmar, M, Kaplan, R, Ledermann, JA |
| المساهمون: | Banerjee, Susana |
| بيانات النشر: | ELSEVIER SCIENCE INC |
| سنة النشر: | 2022 |
| المجموعة: | The Institute of Cancer Research (ICR): Publications Repository |
| مصطلحات موضوعية: | Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Carboplatin, Carcinoma, Ovarian Epithelial, Fallopian Tubes, Female, Humans, Middle Aged, Ovarian Neoplasms, Paclitaxel |
| جغرافية الموضوع: | England |
| الوصف: | BACKGROUND: Standard-of-care first-line chemotherapy for epithelial ovarian cancer is carboplatin and paclitaxel administered once every 3 weeks. The JGOG 3016 trial reported significant improvement in progression-free and overall survival with dose-dense weekly paclitaxel and 3-weekly (ie, once every 3 weeks) carboplatin. However, this benefit was not observed in the previously reported progression-free survival results of ICON8. Here, we present the final coprimary outcomes of overall survival and updated progression-free survival analyses of ICON8. METHODS: In this open-label, randomised, controlled, phase 3 trial (ICON8), women aged 18 years or older with newly diagnosed stage IC-IV epithelial ovarian, primary peritoneal, or fallopian tube carcinoma (here collectively termed ovarian cancer, as defined by International Federation of Gynecology and Obstetrics [FIGO] 1988 criteria) and an Eastern Cooperative Oncology Group performance status of 0-2 were recruited from 117 hospitals with oncology departments in the UK, Australia and New Zealand, Mexico, South Korea, and Ireland. Patients could enter the trial after immediate primary surgery (IPS) or with planned delayed primary surgery (DPS) during chemotherapy, or could have no planned surgery. Participants were randomly assigned (1:1:1), using the Medical Research Council Clinical Trials Unit at University College London randomisation line with stratification by Gynecologic Cancer Intergroup group, FIGO disease stage, and outcome and timing of surgery, to either 3-weekly carboplatin area under the curve (AUC)5 or AUC6 and 3-weekly paclitaxel 175 mg/m2 (control; group 1), 3-weekly carboplatin AUC5 or AUC6 and weekly paclitaxel 80 mg/m2 (group 2), or weekly carboplatin AUC2 and weekly paclitaxel 80 mg/m2 (group 3), all administered via intravenous infusion for a total of six 21-day cycles. Coprimary outcomes were progression-free survival and overall survival, with comparisons done between group 2 and group 1, and group 3 and group 1, in the intention-to-treat ... |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | Print-Electronic; 930; application/pdf |
| اللغة: | English |
| تدمد: | 1470-2045 1474-5488 |
| العلاقة: | S1470-2045(22)00283-2; The Lancet Oncology, 2022, 23 (7), pp. 919 - 930; https://repository.icr.ac.uk/handle/internal/5475Test |
| DOI: | 10.1016/S1470-2045(22)00283-2 |
| الإتاحة: | https://doi.org/10.1016/S1470-2045Test(22)00283-2 https://repository.icr.ac.uk/handle/internal/5475Test |
| حقوق: | http://creativecommons.org/licenses/by/4.0Test/ |
| رقم الانضمام: | edsbas.30404AB |
| قاعدة البيانات: | BASE |
| تدمد: | 14702045 14745488 |
|---|---|
| DOI: | 10.1016/S1470-2045(22)00283-2 |